@article{75aa99f8e5034037b4bc0cf0c1df1399,
title = "Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach",
keywords = "dilated cardiomyopathy, personalized, phenotyping, therapy, CHRONIC HEART-FAILURE, CLINICAL-PRACTICE GUIDELINE, MYOCARDIAL FIBROSIS, ATRIAL-FIBRILLATION, PERIPARTUM CARDIOMYOPATHY, IMMUNOSUPPRESSIVE THERAPY, INCREASE CONTRACTILITY, DIASTOLIC DYSFUNCTION, POSITION STATEMENT, OMECAMTIV MECARBIL",
author = "Verdonschot, \{Job A. J.\} and Hazebroek, \{Mark R.\} and Ware, \{James S.\} and Prasad, \{Sanjay K.\} and Heymans, \{Stephane R. B.\}",
note = "Funding Information: This work was supported by the European Union Commission Seventh Framework Programme under grant agreement No. 305507 (HOMAGE). Kootstra Talent Fellowship of the Maastricht UMC+ to Dr Hazebroek. Dr Ware received funding from Wellcome Trust (107469/Z/15/Z). Dr Prasad has received funding from British Heart Foundation, Rosetrees, and Alexander Jansons Foundation. We also acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2011-ARENA, CVON2016-Early HFPEF, and CVON 2017-ShePREDICTS. This research is cofinanced as a PPP Allowance Research and Innovation by the Ministry of Economic Affairs within Top Sector Life Sciences \& Health.",
year = "2019",
month = jun,
day = "4",
doi = "10.1161/JAHA.119.012514",
language = "English",
volume = "8",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley",
number = "11",
}